Key takeaways
- We found no published study or registered trial of GHK-Cu, BPC-157, TB-500, and KPV together in PubMed and ClinicalTrials.gov searches dated 21 November 2026.
- FDA staff found insufficient clinical safety information to characterize BPC-157 and did not identify clinical studies in their safety reviews of TB-500 or KPV.
- The human records involving these peptides are small, such as a 2024 single-arm BPC-157 pilot in 12 women and a three-patient case series, and none tested the four together (21 Nov 2026).
- A batch report can document what the lab tested, but it cannot establish human safety.
01Where the safety evidence comes from
If you searched “klow peptide side effects”, start by checking what was actually studied. A record for one ingredient or a different combination does not describe the four together.
Human studies
Read what the researchers measured, who took part, and what the study was designed to detect.
FDA surveillance
Keep the agency’s search dates separate from its review date, and a submitted report separate from a finding of cause.
Published cases
Check whether the authors had a comparison group and which other substances were involved.
We found no published study in any species and no registered trial that tested GHK-Cu, BPC-157, TB-500, and KPV together. That finding comes from the 21 November 2026 PubMed and ClinicalTrials.gov searches, which used the blend name and component names, including quoted and unquoted searches in PubMed.
02What human studies and case reports recorded
These records concern individual ingredients or a different combination. Material sold online should not be assumed to match what researchers studied.
| Source and design | What the source recorded | Limit |
|---|---|---|
| Veljaca and colleagues, 2002–2003, placebo-controlled human study of BPC-157 (conference abstracts only, summarised by FDA staff; T2) | Of 32 healthy volunteers randomised, 24 were given BPC-157. The abstracts say the most frequently reported adverse events, headache and flatulence, “occurred with no obvious difference in frequency or severity” between BPC-157 and placebo. | The FDA review notes that the BPC-157 studies were small and short, with limited safety detail. |
| Lee and colleagues, 2024, single-arm human BPC-157 pilot (T2) | The authors reported no adverse events in the 12 women in the study. | No comparison group, and the sample was small. It did not test the blend. |
| Froum and colleagues, 2026, human case series (T2) | The authors described 3 dental patients who received BPC-157 and TB-500 alongside several other agents. Their case-summary table lists “None reported” under adverse events for all three; the text records no treatment-associated adverse events in the first case and no treatment-related complications in the second. | There was no untreated comparison group, and follow-up varied. The cases do not establish a safety profile for either peptide or for the four-peptide blend. |
FDA staff reviewed five small, short human studies involving BPC-157. No serious adverse events appeared in the accounts they reviewed, but the reports gave little safety detail, and it was unclear how most studies monitored for harm. For GHK-Cu, Miller and colleagues’ 2006 randomized human study (T1) had 13 completers and assessed skin redness after laser resurfacing. The abstract does not provide a separate adverse-event tally. Neither source establishes the safety of the blend.
03What FDA surveillance and safety reviews say
FDA Adverse Event Reporting System (FAERS). FDA staff’s searches for TB-500 (through 26 March 2025) and for KPV (through 3 December 2025) retrieved no reports. Our own search of FDA’s public adverse-event data (FAERS, through openFDA, updated to 28 October 2026; searched 21 November 2026) found no report naming KPV or KLOW, and three that name a BPC-157 product and a thymosin product together as suspects; none records whether the thymosin product was TB-500. Two, from 2026, also name other suspect products: one is coded “malaise”, “blood insulin decreased”, “product dispensing error”, “product label issue”, “wrong product administered” and “manufacturing production issue”, the other “histamine abnormal” and “product quality issue”. The third, a 2021 consumer report, is coded “product sterility lacking” and two terms that name a route of administration, which our pages do not print (why). All three are coded as serious. The counts are ours. FDA says reports do not establish that a product caused an event, not every event is reported, and the data cannot establish a rate.
One case described in the FDA briefing. The BPC-157 briefing describes diffuse hyperpigmentation and gingival darkening, meaning darkening of the skin and gums, after a person reported using a product containing BPC-157 and TB-500. The symptoms returned when the same product was used again. FDA staff wrote that the events were “likely due to the drug product” but could not assess whether BPC-157 played a role because the product contained two peptides. This is the staff’s assessment of a submitted case, not an independent clinical study or proof of which ingredient caused it.
FDA’s compounding safety assessments are ingredient-specific. The GHK-Cu entry describes limited human data for the compounded preparations it addresses. FDA staff found “insufficient clinical safety information to characterize the safety profile” of BPC-157. In separate briefings, staff said that potential human safety risks were unknown for TB-500 and for KPV, and that, by the routes proposed to them, BPC-157 and TB-500 each “may pose a significant risk for immunogenicity”; the compounding page says the GHK-Cu preparations it addresses “may pose risk for immunogenicity”. The briefings and compounding page do not provide a risk assessment of the four ingredients together.
04Who took part in the studies?
There is no blend-specific eligibility list in the published studies or registered trials we found in the 21 November 2026 PubMed and ClinicalTrials.gov searches. There are exclusions for individual studies, and they apply only to those studies.
The 2024 BPC-157 pilot studied 12 women aged 39–76; its abstract does not give its eligibility criteria. That is a description of who was studied, not a safety finding for anyone else.
05What we don’t know
- How often any reaction to the four together occurs. The 21 November 2026 searches found no study of the four together, and adverse-event reports cannot give a rate.
- What uncommon or delayed reactions might occur. The component studies and case reports above cannot answer that for the blend.
- Whether a label matches the material in a particular batch. A single purity figure does not show that every listed peptide is present.
If your next question is what a lab actually checked, read how to review a certificate of analysis (COA). For a vial listing four peptides, look for a matching batch number and a separate identity and measurement for each peptide. That is a check on the lab report, not a human safety assessment.
If you suspect a reaction, speak with a clinician. Our reaction reporting guide explains where to file a report.
This is a plain-English summary of public evidence, dated 21 November 2026. It is not medical or legal advice.